Page 153 - 80_01

Luis
García-­-Sevillano

103.
Athanasakis,
K.;
Petrakis,
I.;
Kyriopoulos,
J.
Investigating
the
Value
of
Abatacept
in
the

Treatment
of
Rheumatoid
Arthritis:
A
Systematic
Review
of
Cost-­-Effectiveness
Studies.

ISRN
Rheumatology,
2013.
Disponible
en:
http://dx.doi.org/10.1155/2013/256871.

104.
Kawalec,
P.;
Mikrut,
A.;
Wisniewska,
N.;
Pilc.
A.
The
effectiveness
of
tofacitinib,
a
novel

Janus
kinase
inhibitor,
in
the
treatment
of
rheumatoid
arthritis:
a
systematic
review
and

meta-­-analysis.
Clin
Rheumatol
32,
1415-­-1424
(2013).

105.
Jin,
X.;
Ding,
C.
Belimumab
-­-
An
anti-­-BLyS
human
monoclonal
antibody
for
rheumatoid

arthritis.
Expert
Opinion
on
Biological
Therapy
13,
315-­-322
(2013).

106.
Kurrasch,
R.;
Brown,
J.C.;
Chu,
M.;
Craigen,
J.;
Overend,
P.;
Patel,
B.;
et
al.
Subcutaneously

administered
ofatumumab
in
rheumatoid
arthritis:
a
phase
I/II
study
of
safety,

tolerability,
pharmacokinetics,
and
pharmacodynamics.
J
Rheumatol
40,
1089-­-1096

(2013).

107.
Combe,
B.;
van
Vollenhoven,
R.
Novel
targeted
therapies:
the
future
of
rheumatoid

arthritis?
Mavrilumab
and
tabalumab
as
examples.
Ann
Rheum
Dis
72,
1433-­-1435
(2013).

108.
Genovese,
M.C.;
Fleischmann,
R.M.;
Greenwald,
M.;
Satterwhite,
J.;
Veenhuizen,
M.;
Xie,
L.;

et
al.
Tabalumab,
an
anti-­-BAFF
monoclonal
antibody,
in
patients
with
active
rheumatoid

arthritis
with
an
inadequate
response
to
TNF
inhibitors.
Ann
RheumDis72,
1461-­-1468

(2013).

109.
Gómez
Reino,
J.;
Loza,
E.;
Andreu,
J.
L.;
Balsa,
A.;
Batlle,
E.;
Cañete,
J.
D.;
et
al.
Consenso
SER

sobre
la
gestión
de
riesgo
del
tratamiento
con
terapias
biológicas
en
pacientes
con

enfermedades
reumáticas.
Reumatol
Clin
7,
284-­-298
(2011).

110.
Umicevic
Mirkov,
M.;
Coenen,
M.J.
Pharmacogenetics
of
disease-­-modifying
antirheumatic

drugs
in
rheumatoid
arthritis:
towards
personalized
medicine.
Pharmacogenomics

14,425-­-444
(2013).

150